Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib for chronic pouchitis
ACTRN12621000173897Phase 4Terminated
- Sponsor
- Mater Research
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tofacitinib in pouchitis (4 arms), sponsored by Mater Research. Primary endpoint: Primary: clinical response at end of maintenance. Started Jul 2021; status: terminated.
02
Drugs
03
Conditions
pouchitis
Beyond the preview
Go deeper on ACTRN12621000173897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000173897.